YM 155 is a survivin and ILF3 inhibitor that enhances radiation sensitivity in NSCLC, induces apoptosis in TRAIL-resistant glioma cells, and promotes tumor regression. It also alleviates hypersensitivity in inflammatory pain models, highlighting its potential for oncology and pain management.
Usually ships within 24 hours.